Drugs / anti-CD25 rhMAb
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06364319 | Jul 2026 → Dec 2027 expected | chronic graft versus host disease | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD25 rhMAb | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06364319 ↗ |
| Modality | Monoclonal antibody | “Anti-CD25 rhMAb” NCT06364319 ↗ |
| Route | Intravenous | “administered IV” NCT06364319 ↗ |